Figure 1From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A and B) Box-whisker plots of blood MUC1 mRNA levels in NSCLC patients with progressive disease (PD), stable disease (SD) and partial response (PR) before (B0) and 4Â weeks after the start of gefitinib treatment (B4w). (C and D) Box-whisker plots of blood VEGF mRNA levels in NSCLC patients with PD, SD and PR at B0 and B4w.Back to article page